AASM 2026 Guideline: CBT-I and Medication for Insomnia

Combining Sleep Medicine and Therapy: What the AASM’s 2026 Guideline Means for Chronic Insomnia

A clinical practice guideline issued by the American Academy of Sleep Medicine (AASM) in 2026 makes a specific recommendation for a common clinical dilemma. For adults with chronic insomnia disorder, the AASM suggests the use of combination treatment—starting cognitive-behavioral therapy for insomnia (CBT-I) concurrently with medication—over medication alone. This “conditional” recommendation, based on a systematic review and the GRADE assessment process, provides a new, evidence-based pathway for clinicians and patients.

The panel, chaired by Dr. Daniel J. Buysse of the University of Pittsburgh, clarifies that combination treatment aims to merge the rapid symptom relief of pharmacotherapy with the durable, skills-based benefits of CBT-I. This guideline moves beyond the old question of “therapy or pills?” and asks how they can be strategically used together for better long-term results.

Understanding the Two Pillars: CBT-I and Insomnia Medication

To understand the combination approach, one must first understand the components. They work through fundamentally different mechanisms.

CBT-I: The Behavioral and Psychological Framework

Cognitive-behavioral therapy for insomnia is a multi-component psychological treatment. It is considered the first-line, non-drug intervention for chronic insomnia. CBT-I does not directly induce sleep. Instead, it trains individuals to modify thoughts and behaviors that perpetuate sleep difficulties. Core components include stimulus control (strengthening the bed-sleep connection), sleep restriction (temporarily limiting time in bed to consolidate sleep), cognitive therapy (addressing anxiety about sleep), and sleep hygiene education. The goal is to build permanent self-management skills. A detailed protocol for CBT-I can be found in our dedicated guide.

Pharmacotherapy: The Neurochemical Intervention

Insomnia medications, which include benzodiazepine receptor agonists, sedating antidepressants, melatonin receptor agonists, and others, work by modulating brain chemistry to promote sleepiness or reduce arousal. They can provide relatively fast relief from symptoms like long sleep onset latency or frequent nighttime awakenings. However, effects often diminish with long-term use, and discontinuation can lead to rebound insomnia. Medications manage the symptom but do not typically address the underlying behavioral and cognitive factors that maintain the disorder.

The Rationale for a Combined Strategy

The 2026 AASM guideline stems from an analysis of benefits, harms, and patient preferences. The task force, which included experts from the University of Michigan, Johns Hopkins, and Penn State, identified a potential synergistic effect.

Medication can offer a crucial “bridge” in the early stages of treatment. By reducing acute sleep distress, it may improve a patient’s ability to engage with and adhere to the demanding behavioral components of CBT-I, such as getting out of bed when not sleepy. Simultaneously, CBT-I begins to build the skills needed for sustained sleep health. Theoretically, as these skills solidify, the medication can be tapered, ideally leading to a stable, drug-free outcome with a lower risk of relapse compared to medication monotherapy.

This is a departure from sequential treatment, where one modality is tried fully before the other is added. The concurrent start is a deliberate strategy to capitalize on immediate relief while investing in long-term resilience.

Evidence and the “Conditional” Recommendation Label

The AASM assigned a “Conditional” strength to this suggestion. This is a critical nuance. In the GRADE framework used by the panel, a conditional recommendation means the best choice depends heavily on individual patient context. It signals that while the net benefit likely favors combination therapy, the supporting evidence is not overwhelmingly strong or without caveats.

The guideline notes clinicians must use their judgment and “strongly consider the patient’s values and preferences.” Some patients have a strong aversion to medication, while others may feel an urgent need for symptom relief to function. The available comparative studies show combination therapy often leads to better outcomes than pills alone, but the magnitude of added benefit over starting with CBT-I by itself is less clear. The AASM’s position is that when medication is deemed necessary, adding CBT-I from the outset is the preferred course.

Implementing the Combination: A Clinical Roadmap

For patients considering this approach, understanding the typical process is key.

Initial Assessment and Shared Decision-Making

Treatment begins with a comprehensive evaluation by a sleep specialist to confirm chronic insomnia disorder and rule out other sleep conditions like sleep apnea. The clinician and patient then engage in a detailed discussion about the pros and cons of combination therapy versus other options like CBT-I alone. This conversation covers the patient’s treatment goals, concerns about medication side effects or dependency, readiness for behavioral changes, and logistical factors like access to a qualified CBT-I provider.

Coordinated Treatment Initiation

When combination therapy is chosen, both elements start together. A physician, often a psychiatrist or sleep medicine doctor, prescribes an insomnia medication at an appropriate dose. Concurrently, the patient begins working with a therapist trained in CBT-I, either in-person or via a validated digital platform. Research has shown digital CBT-I can provide lasting benefits. The two providers should ideally communicate to coordinate care.

The Role of Medication Tapering

The medication is not intended to be permanent. A predefined plan for tapering is established early, often around the midpoint of the CBT-I protocol (typically 6-8 weeks). The specific timeline is flexible, based on the patient’s progress, confidence in their new sleep skills, and reduction in sleep-related anxiety. The CBT-I skills become the foundation that supports the patient as the pharmacological “scaffolding” is removed, aiming to prevent the withdrawal effects that often plague medication discontinuation.

It is important to acknowledge that not all patients succeed in tapering off medication, and some may require longer-term pharmacologic management. The combination approach seeks to maximize the chance of durable, drug-free sleep improvement.

Who is This Approach For?

The guideline targets adults with chronic insomnia disorder. It may be particularly relevant for specific subgroups:

• Patients with High Nocturnal Anxiety: Those whose sleep struggle is dominated by racing thoughts and anxiety about not sleeping may benefit from medication’s initial calming effect to break the cycle.
• Individuals Who Previously Failed Single-Modality Treatment: For someone who found CBT-I too difficult without relief or for whom medication lost effectiveness, combination offers a new strategy.
• Cases with Significant Daytime Impairment: When insomnia causes severe daytime dysfunction that threatens job performance or safety, the rapid relief from medication can be protective while CBT-I takes effect.

Combination treatment is less likely to be the first step for individuals with a strong preference to avoid medication, those with substance use histories, or for whom certain insomnia medications pose specific health risks. Considerations for insomnia treatment in the context of addiction are discussed separately.

Key Takeaways

• The American Academy of Sleep Medicine’s 2026 clinical guideline conditionally recommends starting CBT-I and insomnia medication together for adults with chronic insomnia, rather than using medication alone.
• This combination strategy seeks to merge the rapid symptom relief of medication with the durable, skill-based benefits of CBT-I, aiming for better long-term outcomes.
• The “conditional” strength of the recommendation means the decision must be individualized, weighing patient preferences, values, and specific clinical circumstances.
• Successful implementation requires coordinated care, with a planned medication taper supported by the ongoing use of CBT-I skills to minimize rebound insomnia.
• Combination therapy may be a suitable option for those with high sleep-related anxiety, severe daytime impairment, or who have not succeeded with single-modality treatment in the past.
• CBT-I remains the foundational, first-line treatment for chronic insomnia; this guideline addresses how to integrate medication when it is clinically indicated.
• Patients should discuss this approach with a qualified sleep specialist to determine if the potential benefits align with their personal health goals and treatment philosophy.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

---

Sources:
https://pubmed.ncbi.nlm.nih.gov/41975142/
https://pubmed.ncbi.nlm.nih.gov/41963185/
https://pubmed.ncbi.nlm.nih.gov/41963183/